Faron Pharmaceuticals Oy (DI) (FARN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

175.19p
   
  • Change Today:
    -4.81p
  • 52 Week High: 350.00
  • 52 Week Low: 117.50
  • Currency: UK Pounds
  • Shares Issued: 72.01m
  • Volume: 6,947
  • Market Cap: £126.15m

Faron Pharmaceuticals reports year of clinical progress

By Josh White

Date: Wednesday 13 Mar 2024

LONDON (ShareCast) - (Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.
The AIM-traded firm, which is pre-revenue, said most responses were deep and durable, with notable achievements such as complete remission/marrow complete remission (CR/mCR) and partial remission (PR) observed in treated patients.

It said the findings led to the start of the phase two part of the BEXMAB study, guided by the US Food and Drug Administration (FDA), investigating bexmarilimab in combination with standard of care (SoC) in patients with HMA-refractory or relapsed MDS.

Additionally, the FDA granted bexmarilimab orphan drug designation (ODD) for the treatment of acute myeloid leukaemia (AML).

The company also reported that the MATINS study demonstrated promising results in advanced solid tumour patients, with bexmarilimab showing tolerability, activation of intratumoral immunity, and favourable changes in the tumour microenvironment (TME), providing significant clinical benefit.

Throughout 2023, Faron successfully conducted three fundraising rounds, raising €25.7m.

Since the end of the year, in January, Faron dosed the first patients in the phase two part of the BEXMAB Study, marking progress towards evaluating the safety and efficacy of bexmarilimab in combination with SoC in HMA-refractory or relapsed MDS patients.

However, in February, the company disclosed breaches in undertakings agreed in a facilities agreement, leading to several events of default.

Despite that, Faron said it managed to secure €3.2m in subordinated convertible loan arrangements in March, allowing critical payments to third parties under agreed waivers with IPF.

The company said it was now in compliance with all IPF financial covenants, actively engaged in discussions to secure short- and long-term funding.

"I am pleased to report that we have made strong progress in 2023 advancing our BEXMAB study of bexmarilimab, our wholly owned immunotherapy asset," said chief executive officer Dr Markku Jalkanen.

"Throughout the course of the year, we have reported highly encouraging data for bexmarilimab, showing a remarkable overall response rate in both higher-risk frontline MDS patients as well as HMA-failed MDS patients."

Dr Jalkanen described the findings as "highly significant", given the combinations of treatments the patients had previously failed on and the very limited options available for future therapy.

"They provide us with a path to market and only bolster our confidence in the potential of this novel immunotherapy to treat patients with aggressive haematological malignancies."

At 1012 GMT, Faron Pharmaceuticals shares were down 3.67% at 130.05p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

FARN Market Data

Currency UK Pounds
Share Price 175.19p
Change Today -4.81p
% Change -2.67 %
52 Week High 350.00
52 Week Low 117.50
Volume 6,947
Shares Issued 72.01m
Market Cap £126.15m

FARN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
56.86% below the sector average56.86% below the sector average56.86% below the sector average56.86% below the sector average56.86% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 1
Strong Sell 1
Total 3
sell
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

FARN Dividends

No dividends found

Trades for 29-May-2024

Time Volume / Share Price
14:44 5 @ 185.00p
11:35 5,000 @ 182.25p
09:53 541 @ 182.50p
09:23 549 @ 181.20p
09:19 838 @ 181.00p

FARN Key Personnel

CEO Juho Jalkanen
Chair Tuomo Pätsi

Top of Page